Unlocking a Key Pathway in Rheumatoid Arthritis: How a TWIST1-AEBP1 Axis Fuels Disease Progression
A new study published in Arthritis & Rheumatology identifies a critical molecular axis driving synovial hyperplasia and pannus formation in rheumatoid arthritis (RA). Researchers discovered a pathogenic subpopulation of fibroblast-like synoviocytes (FLS) in the synovial sublining that expresses periostin (POSTN). These cells are regulated by the transcription factor TWIST1, which induces the expression of AEBP1. This protein, in turn, activates TGF-β signaling to promote FLS activation, migration, and proliferation, while also driving POSTN expression to stimulate angiogenesis. The study further demonstrates that pharmacological inhibition of TWIST1 with harmine reduces AEBP1 and POSTN levels, limits the expansion of pathogenic FLS, and alleviates joint pathology in a mouse model of collagen-induced arthritis.
Study Significance: This research provides a novel mechanistic understanding of synovial pathology in rheumatoid arthritis, pinpointing the TWIST1-AEBP1-POSTN axis as a central driver of fibroblast activation and neovascularization. For rheumatologists and researchers, these findings highlight a promising new therapeutic target beyond current biologic therapies and JAK inhibitors. Targeting this specific pathway could offer a more precise strategy to halt synovial hyperplasia and pannus development, potentially improving outcomes for patients with aggressive disease.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
